Jiangsu Hanbon Science and Technology
688755
ZERUN CO., LTD
301636
SENXUAN
830946
4
Greenworks
301260
5
Tuoxin Pharmaceutical Group
301089
(Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | 14.86%1.55B | 18.44%8.27B | 20.40%5.2B | 3.69B | 1.35B | 165.89%6.98B | 4.32B | 213.40%2.63B | 126.25%837.86M | 370.33M |
Operating revenue | 14.86%1.55B | 18.44%8.27B | 20.40%5.2B | --3.69B | --1.35B | 165.89%6.98B | --4.32B | 213.40%2.63B | 126.25%837.86M | --370.33M |
Total operating cost | 25.09%1.45B | 21.45%7.5B | 18.59%4.75B | 3.32B | 1.16B | 162.23%6.17B | 4B | 185.27%2.35B | 114.94%825.46M | 384.04M |
Operating cost | 24.21%1.26B | 19.47%6.74B | 14.78%4.16B | --2.97B | --1.01B | 169.91%5.64B | --3.62B | 214.08%2.09B | 129.67%665.87M | --289.93M |
Operating tax surcharges | 355.43%6.54M | -27.73%21.63M | -16.58%11.79M | --5.37M | --1.44M | 115.28%29.93M | --14.14M | 193.51%13.9M | 158.73%4.74M | --1.83M |
Operating expense | 19.68%66.37M | 74.31%280.33M | 89.09%230.11M | --136.4M | --55.45M | 72.89%160.82M | --121.7M | 85.16%93.02M | 133.38%50.24M | --21.53M |
Administration expense | 9.94%44.75M | 16.44%194.08M | 19.57%142.15M | --91.15M | --40.71M | 139.69%166.68M | --118.89M | 65.10%69.54M | 37.01%42.12M | --30.74M |
Financial expense | 179.76%1.49M | 259.27%9.35M | 231.02%6.97M | ---2.65M | ---1.86M | 18.36%-5.87M | ---5.32M | -209.68%-7.19M | 60.05%6.56M | --4.1M |
-Interest expense (Financial expense) | 30.00%7.49M | 65.31%25.39M | 71.08%17.7M | --10.78M | --5.76M | 79.05%15.36M | --10.34M | -53.50%8.58M | 77.85%18.45M | --10.37M |
-Interest Income (Financial expense) | 12.28%-7.3M | 8.96%-25.19M | 3.65%-20.56M | ---15.28M | ---8.33M | -64.59%-27.67M | ---21.34M | -31.35%-16.81M | -62.77%-12.8M | ---7.86M |
Research and development | 44.84%69.19M | 40.10%250.17M | 51.63%195.99M | --116.97M | --47.77M | 89.76%178.57M | --129.26M | 68.22%94.1M | 55.72%55.94M | --35.92M |
Credit Impairment Loss | -43.50%-24.11M | -72.50%-149.6M | -18.33%-107.14M | ---60.12M | ---16.8M | -47.00%-86.72M | ---90.54M | -549.33%-58.99M | -636.07%-9.09M | --1.69M |
Asset Impairment Loss | -14.82%-13.39M | -8.23%-63.49M | -75.77%-43.8M | ---37.75M | ---11.66M | -227.14%-58.67M | ---24.92M | -388.80%-17.93M | -134.55%-3.67M | ---1.56M |
Other net revenue | ||||||||||
Fair value change income | ---221.76K | ---9.56M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Invest income | -22.64%-880.8K | 375.14%11.66M | -828.07%-24.59M | ---3.04M | ---718.19K | -86.96%2.45M | ---2.65M | 182.40%18.82M | -10,760.88%-22.84M | --214.27K |
-Including: Investment income associates | -317.26%-3M | 409.06%11.93M | -173.63%-24.53M | ---2.97M | ---718.19K | 77.16%-3.86M | ---8.96M | 30.13%-16.9M | 18.02%-24.18M | ---29.5M |
Asset deal income | -1,532.08%-75.85K | -79.70%330.56K | -102.90%-97.45K | ---110.21K | ---4.65K | 479.98%1.63M | --3.36M | -676.41%-428.58K | -168.44%-55.2K | --80.65K |
Other revenue | 33.95%41.59M | 166.90%170.95M | 13.86%72.13M | --65.64M | --31.05M | 133.93%64.05M | --63.35M | 30.41%27.38M | 90.62%21M | --11.01M |
Operating profit | -46.08%104.02M | 0.15%730.83M | 32.03%348.23M | 335.76M | 192.91M | 204.14%729.75M | 263.74M | 10,766.18%239.94M | 1.24%-2.25M | -2.28M |
Add:Non operating Income | 367.91%837.6K | -56.75%623.62K | -55.46%500.46K | --315.77K | --179.01K | -17.72%1.44M | --1.12M | -44.78%1.75M | 82.75%3.17M | --1.74M |
Less:Non operating expense | 15.90%22.64K | -84.11%4.22M | -86.54%3.57M | --3.37M | --19.54K | 1,724.45%26.56M | --26.55M | 425.94%1.46M | -88.86%276.83K | --2.48M |
Total profit | -45.70%104.83M | 3.21%727.23M | 44.83%345.15M | 332.7M | 193.07M | 193.30%704.62M | 238.32M | 37,013.57%240.24M | 121.39%647.3K | -3.03M |
Less:Income tax cost | -68.92%10.95M | -38.20%78.29M | -47.31%32.44M | --52.34M | --35.22M | 117.85%126.67M | --61.57M | 496.98%58.15M | -23,904.51%-14.65M | --61.53K |
Net profit | -40.52%93.88M | 12.28%648.95M | 76.92%312.71M | 280.37M | 157.85M | 217.40%577.95M | 176.75M | 1,090.54%182.09M | 595.41%15.29M | -3.09M |
Net profit from continuing operation | -40.52%93.88M | 12.28%648.95M | 76.92%312.71M | --280.37M | --157.85M | 217.40%577.95M | --176.75M | 1,090.54%182.09M | 595.41%15.29M | ---3.09M |
Less:Minority Profit | 111.92%25.33K | 775.65%1.11M | -1,913.40%-710.27K | ---1.5M | ---212.46K | -103.40%-164.08K | --39.17K | 19.55%4.82M | 698.74%4.03M | --505.07K |
Net profit of parent company owners | -40.62%93.86M | 12.06%647.84M | 77.36%313.42M | --281.87M | --158.06M | 226.13%578.12M | --176.71M | 1,474.23%177.27M | 413.46%11.26M | ---3.59M |
Earning per share | ||||||||||
Basic earning per share | -51.26%0.58 | 11.98%4.86 | 76.69%2.35 | --2.11 | --1.19 | 226.32%4.34 | --1.33 | 1,377.78%1.33 | 400.00%0.09 | ---0.03 |
Diluted earning per share | -52.14%0.56 | 10.98%4.75 | 75.57%2.3 | --2.08 | --1.17 | 221.80%4.28 | --1.31 | 1,377.78%1.33 | 400.00%0.09 | ---0.03 |
Other composite income | ||||||||||
Total composite income | -40.52%93.88M | 12.28%648.95M | 76.92%312.71M | 280.37M | 157.85M | 217.40%577.95M | 176.75M | 1,090.54%182.09M | 595.41%15.29M | -3.09M |
Total composite income of parent company owners | -40.62%93.86M | 12.06%647.84M | 77.36%313.42M | --281.87M | --158.06M | 226.13%578.12M | --176.71M | 1,474.23%177.27M | 413.46%11.26M | ---3.59M |
Total composite income of minority owners | 111.92%25.33K | 775.65%1.11M | -1,913.40%-710.27K | ---1.5M | ---212.46K | -103.40%-164.08K | --39.17K | 19.55%4.82M | 698.74%4.03M | --505.07K |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.